Sosei Group Corporation, notes its partner Neurocrine Biosciences Inc., a leading neuroscience-focused biopharmaceutical company, has confirmed its plans to evaluate two new muscarinic agonist candidates in Phase 1 first-in-human clinical studies.
Sosei Group Corporation, notes its partner Neurocrine Biosciences Inc., a leading neuroscience-focused biopharmaceutical company, has confirmed its plans to evaluate two new muscarinic agonist candidates in Phase 1 first-in-human clinical studies.